Past Meetings

Dr. Abdullah Khan

Presented about his recent work on bone marrow organoids (comBO) -- modelling haematopoiesis, immunosenescence and blood cancers in vitro.

• Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies Cancer Discov · 09 Nov 2022
• A proinflammatory stem cell niche drives myelofibrosis through a targetable galectin-1 axis Science Translational Medicine · 9 Oct 2024
• Human Multi-Organoid Platform to Model Immune Dynamics in Cardiac Injury and Disease Circ Res · 26 Sep 2025
• Modelling the pathology and treatment of cardiac fibrosis in vascularised atrial and ventricular cardiac microtissues Front Cardiovasc Med · 01 Sep 2023

• Takeda starts restructuring targeting $1.3B in cost savings. Press release · Mar 2026
• Novartis joins Lilly, AZ in China with $480M expansion Fierce Pharma · Mar 2026
• Gilead pays $3.1B upfront for Tubulis to bolster oncology ADC pipeline Fierce Biotech · Apr 2026

1. What will next-generation in vitro drug screening platforms look like if the goal is to causally map perturbations to multi-omic state changes, then to phenotypes and biological functions, in a way that produces actionable and translational insights for drug discovery?
2. We can programme immune responses. We cannot yet debug them. What roles can immunocompetent organoids play in helping us debug immune responses?
3. How do you disagree effectively when building at the bleeding edge, and how you use storytelling to influence those around you.

• Human colonic organoid injury models against IBD tissue Benchmark · organoid-injury-vs-IBD-tissue comparison (single-cell dissociation/recovery, γ-irradiation, DSS, and cytomix/IFNγ+TNFα+IL1β).